• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British journal of neurosurgery >Active dendritic cell immunotherapy for glioblastoma: Current status and challenges
【24h】

Active dendritic cell immunotherapy for glioblastoma: Current status and challenges

机译：胶质母细胞瘤主动树突状细胞免疫疗法的现状和挑战

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Dendritic cell (DC) immunotherapy is developing as a promising treatment modality for patients with glioblastoma multiforme (GBM). The aim of this article is to review the data from clinical trials and prospective studies evaluating the safety and efficacy of DC vaccines for newly diagnosed (ND)- and recurrent (Rec)-GBM and for other high-grade gliomas (HGGs). By searching all major databases we identified and reviewed twenty-two (n = 22) such studies, twenty (n = 20) of which were phase I and II trials, one was a pilot study towards a phase I/II trial and one was a prospective study. GBM patients were exclusively recruited in 12/22 studies, while 10/22 studies enrolled patients with any diagnosis of a HGG. In 7/22 studies GBM was newly diagnosed. In the vast majority of studies the vaccine was injected subcutaneously or intradermally and consisted of mature DCs pulsed with tumour lysate or peptides. Median overall survival ranged between 16.0 and 38.4 months for ND-GBM and between 9.6 and 35.9 months for Rec-GBM. Vaccine-related side effects were in general mild (grade I and II), with serious adverse events (grade III, IV and V) reported only rarely. DC immunotherapy therefore appears to have the potential to increase the overall survival in patients with HGG, with an acceptable side effect profile. The findings will require confirmation by the ongoing and future phase III trials.
机译：树突状细胞（DC）免疫疗法正在发展为多形胶质母细胞瘤（GBM）患者的一种有前途的治疗方式。本文的目的是回顾来自临床试验和前瞻性研究的数据，这些数据评估了DC疫苗对新诊断（ND）和复发（Rec）-GBM以及其他高级别神经胶质瘤（HGG）的安全性和有效性。通过搜索所有主要数据库，我们确定并审查了22项（n = 22）此类研究，其中20项（n = 20）是I和II期试验，一项是针对I / II期试验的先导研究，另一项是I / II期试验。前瞻性研究。 GBM患者仅在12/22研究中招募，而10/22研究招募了任何诊断为HGG的患者。在7/22研究中，新诊断出GBM。在绝大多数研究中，疫苗是皮下或皮内注射的，由用肿瘤裂解物或肽脉冲的成熟DC组成。 ND-GBM的中位总体生存期介于16.0至38.4个月之间，Rec-GBM的中位总体生存期介于9.6至35.9个月之间。疫苗相关的副作用一般是轻度的（I级和II级），严重的不良事件（III级，IV级和V级）的报道很少。因此，DC免疫疗法似乎具有增加HGG患者总体生存率的潜力，并且具有可接受的副作用。研究结果将需要正在进行的和将来的III期试验予以证实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号